Novo Nordisk axes experimental obesity drugs after success with later-stage meds Biogen bets $1B+ on Denali’s anti-LRRK2 Parkinson’s program Lundbeck’s poor run on schizophrenia trials continues as it cans midstage effort In the face of COVID-19, cell and gene therapy space shows ‘remarkable resilience:’ report Dicerna guides Roche-partnered hepatitis B drug past early test Versant, RA Capital tee T-knife up apply TCRs to solid tumors Teladoc to take over Livongo in $18.5B digital health deal Fighting COVID-19 by luring the virus away from human cells with a decoy target GlaxoSmithKline jumps into myeloma with 'homemade' anti-BCMA drug Blenrep Featured Story | By Ben Adams After seeing later-stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus In December 2017, Denali Therapeutics pulled off what was then biotech’s biggest IPO, pocketing $250 million to develop drugs for Alzheimer’s and Parkinson’s disease. Now, it’s partnering with Biogen on its Parkinson’s program—to the tune of more than $1 billion. read more By Ben Adams Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort. read more By Amirah Al Idrus In the early days of COVID-19, the Alliance for Regenerative Medicine was unsure how the pandemic and its accompanying economic downturn would affect the cell and gene therapy space. Now, the numbers are in—and they’re better than ever. In the first half of 2020, the sector raised $10.7 billion, more than the total it raised in 2019. read more By Nick Paul Taylor Dicerna Pharmaceuticals has shared interim phase 1 data on its Roche-partnered hepatitis B drug RG6346. The trial linked RG6346 to reductions in hepatitis B surface antigen (HBsAg) that suggest the RNAi therapy can hold its own against rival candidates in development at Johnson & Johnson and Vir Biotechnology. read more By Nick Paul Taylor T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic. Versant Ventures and RA Capital Management came together to lead the series A round in the belief T-knife can realize the potential of cell therapies in the treatment of solid tumors. read more By Conor Hale The massive medtech deal reflects the growing importance of virtual healthcare platforms as the world is caught in the wake of the COVID-19 pandemic. read more By Angus Liu COVID-19 infects a person by first binding to the ACE2 receptor on the surface of healthy cells. Scientists led by University of Illinois, Urbana-Champaign, identified a variant of the receptor that might work as a therapeutic candidate by acting as a decoy to lure the virus away. read more By Carly Helfand Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began building its oncology pipeline “pretty aggressively,” as its top cancer R&D exec puts it. Those efforts have finally paid off in an FDA approval for Blenrep, formerly known as belantamab mafodotin. But with a safety warning on its label, the drug's prospects remain to be seen. read more Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: Acorn AI by Medidata, a Dassault Systèmes company Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Lonza Pharma & Biotech A novel spray-dried dispersion platform has been developed to faciliate high drug load applications Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. 18th Annual Discovery on Target Virtual September 16-18, 2020 Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 